Personalized Medicine Providers, FDA Has Your Back

Law360, New York (November 8, 2013, 12:50 PM EST) -- According to the U.S. Food and Drug Administration, already more than 100 approved drugs contain information on genomic biomarkers, highlighting that personalized medicine is no longer a future fantasy, but it is present reality. Recent successes of co-development of personalized medicine including a drug and a companion diagnostic include Vemurafenib/BRAF V600E, approved in 2011 in 3.6 months through an expedited process; Crizotinib/ALK testing, approved in 2011 in 4.9 months with only 255 patients; and Tefinlar/Melkinist/THxID BRAF test approved in 2013.

Recognizing the great promise and challenge...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.